EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, ARVN: Arvinas Inc

28 Oct 25 17:35
LAST:

9.500

CHANGE:
 0.15		OPEN:
9.570		HIGH:
9.620		ASK:
0.000		VOLUME:
2.24M
CHG(%):
1.55		PREV:
9.650		LOW:
9.390		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
28 Oct 259.5709.6209.3909.5002.24M
27 Oct 259.3009.6809.2509.6501.76M
24 Oct 259.2509.5509.0909.2103.46M
23 Oct 259.3209.3759.0109.1603.85M
22 Oct 259.6509.8509.1909.3102.31M
21 Oct 259.7209.9709.6109.6601.6M
20 Oct 259.6209.8209.5309.7201.84M
17 Oct 259.4609.6809.2109.5201.95M
16 Oct 259.43010.2969.3319.6803.91M
15 Oct 258.8009.5608.7809.4603.28M

COMPANY PROFILE

Name:Arvinas Inc
About:Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 3 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company's products also consists ARV 393, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes which is in Phase 1 first-in-human clinical trial; ARV 102 for the treatment of neurodegenerative diseases, which is in Phase 1 clinical trial; and KRAS G12D program is in preclinical development for pancreatic and colorectal cancers. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Sector:Healthcare
Industry:Biotechnology
Address:5 Science Park, New Haven, CT, United States, 06511
Website:https://www.arvinas.com
CUSIP:04335A105
CIK:0001655759
ISIN:US04335A1051
FIGI:BBG00LW7YK82

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:9.371.4%
MA10:9.490.1%
MA20:9.490.1%
MA50:8.4412.6%
MA100:7.9619.3%
MA200:9.671.8%
STO9:29.94
STO14:29.94
RSI14:45.61
WPR14:-46.88
MTM14:-0.09
ROC14:-0.01 
ATR:0.49 
Week High:9.974.9%
Week Low:9.015.4%
Month High:10.308.4%
Month Low:8.151.8%
Year High:29.61211.7%
Year Low:5.9061.0%
Volatility:26.11